Century Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $347.2M
- Price
- $1.93
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.26%
- Volume
- 151.4K
About
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Quick stats
Shares outstanding180.4M
Computed float122.9M
Float / shares68.2%
Cash runway (months)13.5
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001850119
Websitehttps://www.centurytx.com
AI Summary
AI-generated1/8
majorbullishearnings
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Century Therapeutics reported second quarter 2026 financial results with cash, cash equivalents, and investments of $197.2 million, extending the company's operating runway into the first quarter of 2029.
The company completed a pre-IND meeting with the FDA for CNTY-813, reaching alignment on the nonclinical data package and Phase 1/2 trial design, keeping the IND submission on track for the fourth quarter of 2026.
Operating expenses decreased compared to the prior year, with R&D expenses at $19.6 million, while CNTY-308 remains on track to enter the clinic in 2026.